Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer

This publication has 15 references indexed in Scilit:

• Molecular Profiling of Clear Cell Ovarian Cancers
  International Journal of Gynecological Cancer, 2016
• Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
  Nature Medicine, 2015
• Coexistent ARID1A–PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling
  Nature Communications, 2015
• Comprehensive molecular characterization of clear cell renal cell carcinoma
  Nature, 2013
• Surgical and Medical Treatment of Clear Cell Ovarian Cancer
  International Journal of Gynecological Cancer, 2011
• IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer
  Clinical Cancer Research, 2011
• Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
  Science, 2010
• A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
  Annals of Oncology, 2010
• Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma
  International Journal of Gynecological Cancer, 2008
• Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
  New England Journal of Medicine, 2007